Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,477 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypersensitivity, Immune System Diseases Clear all

Conditions: Atopic Dermatitis
Interventions: ADX-629 (Open-label); Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bexley, Ohio

Conditions: Allergic Conjunctivitis
Interventions: TL-925, Placebo; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Rhinitis
Interventions: fluticasone furoate, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo, 0.15% azelastine hydrochloride; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Allergy
Interventions: Short Ragweed Pollen Allergenic Extract, Placebo; Biological
Lead sponsor: Greer Laboratories; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Warrenton, Virginia

Conditions: Asthma
Interventions: Breathing exercise; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Asthma
Interventions: Tiotropium, Salmeterol, Formoterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more

Conditions: Sarcoidosis, Pulmonary
Interventions: Glucocorticoid (prednisone or prednisolone); Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 10
States / cities: Birmingham, Alabama • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Allergy
Interventions: Placebo, Xolair; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Asthma
Interventions: Fluticasone Propionate (FP); Drug
Lead sponsor: Dey; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rock Hill, South Carolina

Conditions: Asthma
Interventions: Montelukast, Singulair; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Photo therapy; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Asthma
Interventions: Fluticasone Furoate, Fluticasone Furoate/Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Huntington Beach, California

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more

Conditions: Allergic Conjunctivitis
Interventions: RX-10045, Vehicle for RX-10045 arm; Drug
Lead sponsor: C.T. Development America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Atopic Dermatitis (AD), Asthma
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lymphoma
Interventions: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them; Drug
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hereditary Angioedema Types I and II
Interventions: C1-esterase inhibitor; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 6 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more

Conditions: Asthma
Interventions: Remote Coach plus Asthma Module, Asthma Module- No Coach, CHADIS- no Asthma Module; Behavioral
Lead sponsor: Total Child Health, Inc.; Industry
Eligibility: Up to 19 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peanut Allergy
Interventions: DBV712 250 mcg; Combination Product
Lead sponsor: DBV Technologies; Industry
Eligibility: 2 Years to 17 Years
U.S. locations: 1
States / cities: Madison, Connecticut

Conditions: Hypersensitivity Reactions, Allergic Contact Dermatitis
Interventions: Silk fibroin (SYLKE), 2-octyl cyanoacrylate mesh (Dermabond PRINEO); Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoidosis
Interventions: Cytotoxic drug; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 15 Years to 90 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more

Search by objective public record fields.

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

Breathing Exercises for Asthma

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils

A 12-Week Study in Adult Subjects With Asthma

Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

Reproductive Health in Men and Women With Vasculitis

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Web System for Engaging Families & Doctors in Continuous Asthma Quality Improvement

Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery

Use of Immunosuppressive Therapy for Sarcoidosis

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)